Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTEGRATED GENETICS MILKING TUFTS TRANSGENIC LIVESTOCK R&D

Executive Summary

INTEGRATED GENETICS MILKING TUFTS TRANSGENIC LIVESTOCK R&D with the initial focus on production of TPA and protein C under an agreement announced Oct. 11. The terms of the three-year R&d agreement with Tufts University School of Veterinary Medicine provide that Integrated Genetics is providing over $ 1 mil. in funding. The three-year program to pursue development of livestock for pharmaceutical production "follows the successful completion of a joint study by Tufts and Integrated Genetics, designed to assess the feasibility of utilizing livestock for the production of pharmaceuticals in milk," the release explains. The feasibility of animals producing human proteins first received public attention in November 1987, with the publication of a joint Integrated Genetics/NIH study of transgenic mice induced to produce TPA in their milk ("The Pink Sheet," Nov. 2, 1987, p. 21). To produce transgenic animals capable of excreting pharmaceutical proteins in their milk, Integrated Genetics explained that genetic material is microinjected into a fertilized single cell embryo to be implanted in the recipient mother for gestation. The gene fragments include both the gene for the desired therapeutic protein as well as regulatory sequences that control the cells through which the protein will be expressed. When the transgenic animals are bred, their offspring will also produce the pharmaceutical protein in their milk. Future generations will likewise carry this production capability. "Since several livestock species produce large volumes of milk at low cost, transgenic protein production is likely to have substantial cost advantages over other methods," the release states. The project's initial focus is to use goats for protein production, with the possibility of introducing cows and other livestock in the future. The Tufts veterinary school is currently discussing R&D projects using transgenic animal technology with several other biotech and pharmaceutical firms. The school is also working with Transgenic Sciences on transgenic poultry. The patentability of transgenic animals has been the subject of congressional hearings. After Harvard University received the first patent for a transgenic animal in April, for genetically altered mice, legislation was introduced requiring a two-year moratorium on the issuance of additional transgenic animal patents. That bill (HR 3119) was defeated in the House Judiciary/Courts Subcommittee in July. A replacement bill (HR 4970) sponsored by Rep. Kastenmeier (D-Wis.), which would exempt single-family farms from transgenic animal patents, has passed the House.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel